MLI Certified Activities

Search
Generic filters
Credit Amount (at least)
Course Types
Learner Specialties
Therapeutics Areas
Addressing the Unmet Needs of Patients With Moderate to Severe Psoriasis: A Visual Exploration of Disease Pathogenesis and the Clinical Potential of Targeting the TYK2 Pathway as a Novel Nonbiologic Oral Therapeutic Option
In this activity, an expert in dermatology discusses unmet needs of patients with moderate to severe psoriasis and the clinical potential of targeting the TYK2 pathway as a novel nonbiologic oral therapeutic option.
Approaching Rheumatoid Arthritis With Precision: Translating the Insight Provided by Biomarkers Into Improved Patient Care and Outcomes
In this activity, experts in rheumatology discuss how biomarkers can be used to inform treatment strategies and improve care and outcomes in patients with rheumatoid arthritis.
Conversations on the New Wave of Innovative Therapy in Follicular Lymphoma: Implications for Personalized Medicine
In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts also provide their insights on baseline factors that can help identify patients who may benefit from the use of such innovative agents, as well as safety management.
Acute Hepatic Porphyria: Disease Diagnosis and Revelations Regarding the Role of siRNA Therapy
In this activity, a leading expert in the management of acute hepatic porphyria (AHP) discusses recent evidence and recommendations for treating AHP and highlights the rationale and role of a new siRNA-based therapeutic option.
A Visual Exploration of Antisense Oligonucleotide Therapies in Amyotrophic Lateral Sclerosis
In this activity, an expert in neurology discusses the use of antisense oligonucleotide therapies in patients with amyotrophic lateral sclerosis (ALS).
Visualizing the Present and Future of CLL: How Innovative Therapies and State-of-the-Art Combinations are Transforming Patient Care
Modern management of chronic lymphocytic leukemia (CLL) has been transformed by innovative therapeutics, including BTK and BCL-2 inhibitors, in a range of patient populations and treatment settings—but what is the next step? In this activity, an expert clinician addresses that question and reviews evidence on emerging targeted options and novel combination strategies likely to affect patient care.
New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer: Practical Strategies for Optimal Clinical Integration of Adjuvant CDK4 and 6 Inhibitor Therapy
The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recurrence. With great progress in clinical research come questions about how to translate it into improvements in clinical practice. Which patients are/are not candidates for adjuvant CDK4 and 6 inhibition based on the recent FDA approval and updated ASCO recommendations? What is the role of Ki-67 testing in determining patient eligibility for treatment? How should risk be assessed to inform treatment selection and improve outcomes in patients with HR+/HER2- EBC? These questions and others are answered in this succinct educational activity to help make the most of this new adjuvant therapy option for the benefit of patients.
The Evolving Role of Oxybate Agents in the Management of Narcolepsy: A Visual Exploration of Individualized Care
In this infographic-based activity, an expert in sleep medicine discusses the signs and symptoms of narcolepsy and shares evidence-based approaches to individualizing care.
Across the Age Spectrum: Expert Insights on Emerging Uses of Targeted Therapy for the Treatment of Uncontrolled Moderate-to-Severe Asthma
In this activity, an expert in pulmonology discusses the latest clinical research and treatment guidelines on approved biologic therapies for the management of adult and pediatric patients with uncontrolled moderate to severe asthma.
Visualizing Progress for TP53 Mutant AML: A Pathology-Guided Journey through Diagnostic Principles and Modern Treatment
In this activity, an expert pathologist discusses the prognostic relevance of TP53 mutations, current diagnostic tools and principles for capturing TP53-mutated acute myeloid leukemia (AML), and new developments with innovative therapy for TP53-mutated AML.
Recent Advances in the Management of Depressive Disorders: Preparing for a Shift in the Treatment Paradigm
Recent Advances in the Management of Depressive Disorders: Preparing for a Shift in the Treatment Paradigm
Genomics and Hematologic Malignancies: Beyond the Philadelphia Chromosome
It has been 60 years since the discovery of a chromosomal abnormality in CML; the so-called Philadelphia chromosome. Since then genomics has revolutionized cancer care and the impact in hematologic malignancies is plentiful. Healthcare providers must understand the science to be able to apply in practice and communicate complex information to patients and caregivers. This session will provide an overview of foundational genomic concepts and how genomics is applied across the care continuum for hematologic cancers. Case studies examining the application of testing to “real life” situations will be presented and resources for patients will be shared.
Fulfilling Unmet Treatment Needs for Patients with IgE-Mediated Food Allergies: An Animated Exploration of Emerging Targeted Therapy
In this activity, an allergy expert discusses the mechanism of action and current treatment approaches for managing IgE-mediated food allergies.
New Insights How Does Real-World Evidence Influence VTE Management? A Visual Exploration of Real-World Studies of DOACs
In this activity, a vascular medicine expert discusses real-world evidence (RWE) for treating patients with or at risk for venous thromboembolism (VTE) with direct oral anticoagulants (DOACs).
Optimally Sequencing Modern TKIs in GIST: Expert Perspectives From an Interprofessional Sarcoma Team
While TKIs have been a mainstay in the first three lines of treatment for patients with gastrointestinal stromal tumors (GISTs), new discoveries and emerging science have led to the development of newer agents that address treatment resistance. Known as modern TKIs, these agents have a confirmed role in the treatment of patients with specific mutations or in later-line settings and are now being tested in earlier-stage disease. While oncologists, oncology nurses, and other members of the interdisciplinary cancer care team have new opportunities for increasing survival and improving QOL in their patients with unresectable/metastatic GIST, they are also faced with more complex treatment paradigms that must account for mutation profiling, treatment selection/sequencing, symptom and AE management, psychological support, and nutritional considerations. Join our experts to hear how all members of the cancer care team can work together to effectively incorporate these modern TKIs into clinical practice.
Episode 3 of 4 of the series on: The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes
Avoiding Roadblocks in Coordinating CAR-T Therapy for B-cell Lymphoma: Practical Tips for Community Oncology Clinicians, episode 3 of the 4-part educational initiative The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes, is designed for community-based oncology clinicians. This CE activity includes conversations among CAR-T experts and a community clinician; it includes patient video clips and numerous downloadable resources including a directory of CAR-T treatment centers organized by state. This activity focuses on managing logistics associated with CAR-T therapy, including common misperceptions, the numerous services offered by treating centers, and how to overcome roadblocks for your patients.
The Rising Tide of Novel BTK Inhibitors: Case-Based Guidance on Overcoming Intolerance, Resistance, and Other Clinical Challenges in B-Cell Cancers
The Rising Tide of Novel BTK Inhibitors: Case-Based Guidance on Overcoming Intolerance, Resistance, and Other Clinical Challenges in B-Cell Cancers
A New Treatment Era for Light-Chain Amyloidosis:Interprofessional Lessons From a Center of Excellence
In this activity, a panel of experts discusses a team-based approach to the management of light chain (AL) amyloidosis. Hear from Suzanne Lentzsch, MD, PhD, Mathew S. Maurer, MD, and Margaret Cuomo, MSN, FNP-C, from the Columbia University Medical Center, as they give insights on diagnostic strategies for AL amyloidosis and as they explore treatment guidelines, evidence, and safety concerns of established and novel approaches to managing AL amyloidosis.
Episode 2 of 3: Overcoming Barriers to Prescribing: A Med Table Talk™: Targeted Therapy in Atopic Dermatitis Series
In episode 2 of the 3-part educational initiative TRANSFORMING TARGETED THERAPY IN ATOPIC DERMATITIS: APPLYING EMERGING DATA AND EVOLVING BEST PRACTICES TO IMPROVE OUTCOMES, dermatologists and allergists discuss overcoming barriers to the use of oral JAK inhibitors. This activity focuses on the mechanistic rationale for the benefit and risk profiles of oral JAK inhibitors, how to address the black box warnings, and making treatment decisions based on patients’ values and goals.
An Animated Exploration of Chronic Fibrosing Interstitial Lung Disease: From Diagnosis to Management in the Era of Antifibrotic Therapy
In this activity, an expert in interstitial lung disease discusses the diagnosis of and novel and emerging therapies to treat chronic fibrosing interstitial lung disease.
Easing the Burden of Hypereosinophilic Syndrome: An Animated Exploration of the Role of Targeted Therapy to Improve Patient Outcomes
In this activity, an expert in hypereosinophilic syndrome discusses the burden, symptoms, and differential diagnosis of the disease, as well as the latest data on treatment.
Episode 3 of 3: Practical Approaches to Enhance Care for Individuals with Atopic Dermatitis: A Med Table Talk™: Targeted Therapy in Atopic Dermatitis Series
In episode 3 of the 3-part educational initiative TRANSFORMING TARGETED THERAPY IN ATOPIC DERMATITIS: APPLYING EMERGING DATA AND EVOLVING BEST PRACTICES TO IMPROVE OUTCOMES, dermatologists and allergists discuss practical approaches to improve care for patients with moderate-to-severe disease. Topics include best practices for vaccination, considerations for patients in special populations, and advocating for access to novel therapies.
Taking the Fight to AML: Oncology Nurse Perspectives, Principles, and Practice in an Era of Innovative Therapies
In this activity, two expert nurse panelists use case-based teaching to illustrate solutions to clinical challenges associated with nursing care in the modern acute myeloid leukemia (AML) treatment landscape in which innovative therapies (including targeted agents, newer cytotoxics, and epigenetic approaches) are now core patient treatment strategies.
Complementary Actions All Around: Lowering Cardiometabolic Risks While Achieving Glycemic Targets with GLP-1 RAs
How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you’ll be able to take the post-test and claim credit quickly!
Scroll to Top